吉利德科学Gilead Sciences（GILD）2025年第一季度业绩报告「NASDAQ」（英文版）（15页）.pdf

1、GILEADSCIENCESANNOUNCESFIRSTQUARTER2025FINANCIALRESULTSProductSalesExcludingVekluryIncreased4%Year-Over-Yearto$6.3billionBiktarvySalesIncreased7%Year-Over-Yearto$3.1billionFosterCity,CA,April24,2025-GileadSciences,Inc.(Nasdaq:GILD)announcedtodayitsfirstquarter2025resultsofoperations.“Gileadhadastron

2、gstarttotheyeardrivenbyexcellentcommercialandclinicalexecutionalongwithdisciplinedexpensemanagement,”saidDanielODay,GileadsChairmanandChiefExecutiveOfficer.“Ourbasebusinessgrew4%year-over-year,primarilyledbyBiktarvyscontinuedstrength,andweannouncedpositivetoplinePhase3resultsforTrodelvypluspembroliz

3、umabinfirstlinePD-L1+metastatictriplenegativebreastcancer.WiththeupcomingJunePDUFAdateforlenacapavirforHIVprevention,andcontinuedprogressacrossourdiversepipeline,welookforwardtobuildingonourpositivemomentumthroughouttheyear.”FirstQuarter2025FinancialResultsTotalfirstquarter2025revenueof$6.7billionre

4、mainedflatcomparedtothesameperiodin2024,withlowerVeklury(remdesivir)andOncologysalesoffsetbyhigherHIVandLiverDiseasesales.Dilutedearnings(loss)pershare(“EPS”)was$1.04inthefirstquarter2025comparedto$(3.34)inthesameperiodin2024.Theincreasewasprimarilydrivenbyprioryearchargesthatdidnotrepeat,includingt

5、heimpactofa$3.9billionacquiredin-processresearchanddevelopment(IPR&D)expenserelatedtotheacquisitionofCymaBayTherapeutics,Inc.(“CymaBay”),aswellasapre-taxIPR&Dimpairmentof$2.4billionrelatedtoassetsacquiredbyGileadfromImmunomedics,Inc.(“Immunomedics”)in2020.Thisincreasewaspartiallyoffsetbyhighertaxexp

6、enseandhighernetunrealizedlossesonequityinvestmentsinthefirstquarter2025.Non-GAAPdilutedEPSwas$1.81inthefirstquarter2025comparedto$(1.32)inthesameperiodin2024.TheincreasewasprimarilydrivenbytheprioryearIPR&DexpenserelatedtotheCymaBayacquisition.AsofMarch31,2025,Gileadhad$7.9billionofcashandcashequiv